



## ASX RELEASE

### Leading US oncologist joins Race scientific advisory team

**4 October 2016, Perth, Australia:** Race Oncology Ltd (ASX: RAC) is pleased to announce that it has signed a consulting agreement with Associate Professor Roland Walter, MD PhD MSc, a leading international oncologist and AML expert, based at the Fred Hutchinson Cancer Research Center in Seattle. Under the agreement, Dr Walter will assist Race Oncology in developing clinical protocols for Bisantrene and optimising the drug's clinical positioning in the treatment of AML (Acute Myeloid Leukaemia).

"Dr Walter is an eminent haematological oncologist and we are privileged to have a thought leader of his stature on board as a scientific advisor," said Race Oncology CEO, Peter Molloy. "Bisantrene meets an important unmet medical need in AML and Dr Walter's expertise will help us ensure the decisions we make about its market positioning and the direction of future clinical studies are informed by the latest thinking in the field."

Dr Walter currently holds several prestigious positions including Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor of Medicine, Division of Hematology/Department of Medicine, University of Washington School of Medicine; and Adjunct Associate Professor, Department of Epidemiology, University of Washington School of Public Health. Dr Walter's research program is focused on AML and most recently, he chaired an education session on the treatment of AML at the American Society of Hematology (ASH) meeting in December 2015. Dr Walter is extensively published, has received numerous honours and awards, and has editorial responsibilities at key journals including *American Journal of Blood Research*, *Journal of Hematological Malignancies* and *International Journal of Hematologic Oncology*.

#### About Race Oncology

Race Oncology Ltd is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit [raceoncology.com](http://raceoncology.com) for more information.

For more information, contact:

**Peter Molloy**

Managing Director

T: +61 (0) 3 9097 1656

M: +61 (0) 418 174 816